Pune, Maharastra -- (SBWIRE) -- 10/08/2015 -- The epilepsy drugs market in Europe to grow at a CAGR of 3.22% over the period 2014-2019. Reformulated medicines usually have better tolerability, reduced dosing regimen, and decreased developmental costs than original drugs. Few vendors are focusing on developing such drugs instead of manufacturing new drugs. For instance, Neurontin by Pfizer, Keppra by UCB, and Trobalt by GlaxoSmithKline are film-coated tablets that were recently launched in the market.

Browse Epilepsy Drugs Market in Europe - Market Analysis 2015-2019 Report.

According to the Epilepsy Drugs Market in Europe - Market Analysis 2015-2019 report, growing patient population will lead to an increase in the consumption of anti-epileptic drugs. The market has significant levels of unmet medical needs. Currently, there are no safe and efficient disease-modifying drugs present in the market. Available drugs have many side effects, which decreases patient compliance. Any drug that can completely cure the disease will drive the market.

Further, the Epilepsy Drugs Market in Europe - Market Analysis 2015-2019 report states that patent expiries of major branded drugs will decrease their market sales. This will decrease the market revenue of innovator drugs, paving the way for their generic forms.

The report includes the present scenario and the growth prospects of the epilepsy drugs market in Europe for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of epilepsy.

Purchase a Copy of Report at http://www.rnrmarketresearch.com/contacts/purchase?rname=420223.

The report, Epilepsy Drugs Market in Europe 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. It covers the market size and forecast as well as market segmentation and pipeline landscape. The report includes a discussion of the key vendors operating in this market.

Inquire for DISCOUNT